Patents by Inventor John Richard Morphy

John Richard Morphy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted [1,2,4]triazolo[4,3-a]pyrazines as phosphodiesterase inhibitors
    Patent number: 11453673
    Abstract: The present invention provides a compound of Formula I: wherein R1 is methyl, ethyl or cyclopropyl; R2 is hydrogen, methyl, or ethyl; R3 is methyl or AA; and R4 is C2-C4 alkyl, BB; or a pharmaceutically acceptable salt thereof; for use as a PDE1 inhibitor.
    Type: Grant
    Filed: January 13, 2019
    Date of Patent: September 27, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: Nicholas Paul Camp, Chafiq Hamdouchi, Jayana Pankaj Lineswala, John Richard Morphy, Qing Shi
  • [1,2,4]Triazolo[4,3-A]pyrazin-6(5H)-one derivatives
    Patent number: 11180503
    Abstract: The present invention provides a compound of Formula (I), wherein X is H or C1-C3 alkyl optionally substituted with hydroxyl; Y is H, hydroxy, or methyl; R is ethyl, n-propyl, cyclopropyl, or Formula (II); and A is methyl, cyclopropyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X and Y are both H and R is n-propyl, then A is other than methyl; for use as a human PDE1 inhibitor.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: November 23, 2021
    Assignee: ELI LILLY AND COMPANY
    Inventors: Michael James Genin, William Glen Holloway, Richard Duane Johnston, John Richard Morphy, Qing Shi
  • Compounds useful for inhibiting ROR?t
    Patent number: 11008336
    Abstract: The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof, formula (A).
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: May 18, 2021
    Assignee: Eli Lilly and Company
    Inventors: Christian Alexander Clarke, Charles Willis Lugar, III, John Richard Morphy, Timothy Ivo Richardson, Helene Rudyk, Selma Sapmaz, Ryan Edward Stites, Grant Mathews Vaught
  • [1,2,4]TRIAZOLO[4,3-A]PYRAZIN-8-ONE DERIVATIVES
    Publication number: 20200399277
    Abstract: The present invention provides a compound of Formula I: wherein R1 is methyl, ethyl or cyclopropyl; R2 is hydrogen, methyl, or ethyl; R3 is methyl or AA; and R4 is C2-C4 alkyl, BB; or a pharmaceutically acceptable salt thereof; for use as a PDE1 inhibitor.
    Type: Application
    Filed: January 13, 2019
    Publication date: December 24, 2020
    Inventors: Nicholas Paul CAMP, Chafiq HAMDOUCHI, Jayana Pankaj LINESWALA, John Richard MORPHY, Qing SHI
  • [1,2,4]TRIAZOLO[4,3-A]PYRAZIN-6(5H)-ONE DERIVATIVES
    Publication number: 20200123154
    Abstract: The present invention provides a compound of Formula (I), wherein X is H or C1-C3 alkyl optionally substituted with hydroxyl; Y is H, hydroxy, or methyl; R is ethyl, n-propyl, cyclopropyl, or Formula (II); and A is methyl, cyclopropyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X and Y are both H and R is n-propyl, then A is other than methyl; for use as a human PDE1 inhibitor.
    Type: Application
    Filed: July 26, 2018
    Publication date: April 23, 2020
    Applicant: Eli Lilly and Company
    Inventors: Michael James Genin, William Glen Holloway, Richard Duane Johnston, John Richard Morphy, Qing Shi
  • Compounds useful for inhibiting ROR-gamma-t
    Patent number: 10603320
    Abstract: The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof. Formula (I).
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: March 31, 2020
    Assignee: Eli Lilly and Company
    Inventors: Charles Willis Lugar, III, John Richard Morphy, Timothy Ivo Richardson, Helene Catherine Eugenie Rudyk, Selma Sapmaz, Ryan Edward Stites
  • COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T
    Publication number: 20200048279
    Abstract: The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof, formula (A).
    Type: Application
    Filed: February 27, 2018
    Publication date: February 13, 2020
    Inventors: Christian Alexander Clarke, Charles Willis Lugar, III, John Richard Morphy, Timothy Ivo Richardson, Helene Rudyk, Selma Sapmaz, Ryan Edward Stites, Grant Mathews Vaught
  • COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T
    Publication number: 20200009139
    Abstract: The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof. Formula (I).
    Type: Application
    Filed: February 27, 2018
    Publication date: January 9, 2020
    Inventors: Charles Willis Lugar, III, John Richard Morphy, Timothy Ivo Richardson, Helene Catherine Eugenie Rudyk, Selma Sapmaz, Ryan Edward Stites
  • Compounds useful for inhibiting ROR-gamma-t
    Patent number: 9598431
    Abstract: The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof:
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: March 21, 2017
    Assignee: Eli Lilly and Company
    Inventor: John Richard Morphy
  • COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T
    Publication number: 20170066781
    Abstract: The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof:
    Type: Application
    Filed: September 6, 2016
    Publication date: March 9, 2017
    Inventor: John Richard Morphy
  • Compounds with medicinal effects due to interaction with the glucocorticoid receptor
    Patent number: 7960365
    Abstract: The invention provides for compounds having the structure according to the formula I wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; R1 is hydrogen, halogen, CN or (1C-4C)alkyl; R2 is hydrogen, halogen or optionally fluorinated (1C-3C)alkoxy; R3 and R5 are independently hydrogen, optionally halogenated (1C-4C)alkyl, optionally halogenated (1C-4C)alkoxy, optionally halogenated aryl(1C-4C)alkoxy, optionally halogenated (1C-4C)alkenyl or hydroxylmethyl; R4 is hydrogen, halogen, optionally halogenated (1C-4C)alkoxy or optionally halogenated aryl(1C-4C)alkoxy; R6 is hydrogen, benzyl, optionally substituted with one or more halogens or (1C-4C)alkyl, or R6 is optionally halogenated (1C-4C)alkyl; each R7 independently is hydrogen, halogen, optionally halogenated (1C-4C)alkyl or optionally halogenated (1C-4C)alkoxy and pharmaceutically suitable acid addition salts thereof for use as glucocorticoid receptor modulators, in particular for treatment of central nervous system disorders.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: June 14, 2011
    Assignee: N.V. Organon
    Inventors: Niall Morton Hamilton, Simon James Anthony Grove, Michael John Kiczun, John Richard Morphy, Brad Sherborne, Peter Thomas Albert Littlewood, Angus Richard Brown, Celia Kingsbury, Michael Ohhlmeyer, Koc-Kan Ho, Steven G. Kultgen
  • 2-(1-oxo-1-isoquinolin-2-yl)acetamide derivatives
    Patent number: 7906504
    Abstract: Disclosed herein are 2-(1-oxo-1H-isoquinolin-2-yl)acetamide derivative of formula I, or pharmaceutically acceptable salts or solvates thereof wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions comprising 2-(1-oxo-1H-isoquinolin-2-yl)acetamide derivatives according to the present invention and their use in therapy.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: March 15, 2011
    Assignee: N.V. Organon
    Inventors: Jeffrey Letourneau, Jui-Hsiang Chan, Patrick Jokiel, Michael Ohlmeyer, Irina Neagu, Christopher Riviello, John Richard Morphy, Susan Elizabeth Napier, Koc-Kan Ho
  • 6-substituted isoquinoline derivatives
    Patent number: 7893088
    Abstract: The present invention relates to 6-substituted isoquinoline derivatives having the general Formula I wherein X is O, S or NH; Y is OH or NH2; m is 0, 1 or 2; n is 0 or 1; o is 0 or 1; R1 is H, when Y is NH2; or R1 is H, (C1-4)alkyl or halogen, when Y is OH; R2 and R3 are independently H, (C1-4)alkyl or halogen; R4 is H or (C1-6)alkyl, optionally substituted with halogen, (C3-7)cycloalkyl, (C6-10)aryl or a saturated 5- or 6-membered heterocyclic ring comprising 1-3 heteroatoms independently selected from O, S and N, the (C6-10)aryl and heterocyclic ring being optionally substituted with (C1-4)alkyl, (C1-4)alkyloxy or halogen; R5 is H or (C1-4)alkyl; or a pharmaceutically acceptable salt thereof, with the proviso that the compounds of Formula I wherein X is O, Y is OH , n is 0 and m+o=2 are excluded, to pharmaceutical compositions comprising the same, as well as to the use of said 6-substituted isoquinoline derivatives for the preparation of a medicament for the treatment of ROCK-I related disorders such as
    Type: Grant
    Filed: August 16, 2007
    Date of Patent: February 22, 2011
    Assignee: N.V. Organon
    Inventors: Peter Christopher Ray, Steven Laats, John Richard Morphy, Brad Sherborne
  • 2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as vasopressin V3 antagonists
    Patent number: 7807686
    Abstract: The present invention relates to 2-(4-oxo4H-quinazolin-3-yl) acetamicle derivatives of formula (I), and to their use as vasopressin V3 antagonists, particularly for the treatment of depression.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: October 5, 2010
    Assignee: N.V. Organon
    Inventors: Jeffrey Letourneau, Christopher Riviello, Koc-Kan Hoc, Jui-Hsiang Chan, Michael Ohlmeyer, Patrick Jokiel, Irina Neagu, John Richard Morphy, Susan Elizabeth Napier
  • 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists
    Publication number: 20080214553
    Abstract: The present invention relates to 2-(4-oxo4H-quinazolin-3-yl)acetamicle derivatives of formula (I), and to their use as vasopressin V3 antagonists, particularly for the treatment of depression.
    Type: Application
    Filed: March 10, 2006
    Publication date: September 4, 2008
    Inventors: Jeffrey Letourneau, Christopher Riviello, Koc-Kan Ho, Jui-Hsiang Chan, Michael Ohlmeyer, Patrick Jokiel, Irina Neagu, John Richard Morphy, Susan Elizabeth Napier
  • 6-SUBSTITUTED ISOQUINOLINE DERIVATIVES
    Publication number: 20080045566
    Abstract: The present invention relates to 6-substituted isoquinoline derivatives having the general Formula I wherein X is O, S or NH; Y is OH or NH2; m is 0, 1 or 2; n is 0 or 1; o is 0 or 1; R1 is H, when Y is NH2; or R1 is H, (C1-4)alkyl or halogen, when Y is OH; R2 and R3 are independently H, (C1-4)alkyl or halogen; R4 is H or (C1-6)alkyl, optionally substituted with halogen, (C3-7)cycloalkyl, (C6-10)aryl or a saturated 5- or 6-membered heterocyclic ring comprising 1-3 heteroatoms independently selected from O, S and N, the (C6-10)aryl and heterocyclic ring being optionally substituted with (C1-4)alkyl, (C1-4)alkyloxy or halogen; R5 is H or (C1-4)alkyl; or a pharmaceutically acceptable salt thereof, with the proviso that the compounds of Formula I wherein X is O, Y is OH , n is 0 and m+o=2 are excluded, to pharmaceutical compositions comprising the same, as well as to the use of said 6-substituted isoquinoline derivatives for the preparation of a medicament for the treatment of ROCK-I related disorders such as
    Type: Application
    Filed: August 16, 2007
    Publication date: February 21, 2008
    Applicant: N.V. Organon
    Inventors: Peter Christopher Ray, Steven Laats, John Richard Morphy, Brad Sherborne
  • N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives
    Patent number: 7126027
    Abstract: The present invention relates to N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives having the general formula I wherein n is 0, 1, 2 or 3; R1 and R2 are independently H, (C1-4)alkyl or (C1-4)alkyloxy; R3 is (C3-8)alkyl, (C4-7)cycloalkyl, (C4-7)cycloalkyl (C1-3)alkyl, (C6-12)aryl(C1-3)alkyl (wherein the aryl moiety is optionally substituted with 1–3 substituents selected from (C1-4)alkyl, (C1-4)alkyloxy, halogen, trifluoromethyl and methoxycarbonyl), or (C4-9)heteroaryl(C1-3)alkyl; or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives, and to the use of these N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives in the treatment of disorders or conditions which are responsive to inhibition of the GlyT-2 transporter, such as muscle spasticity, epilepsy and, particularly, acute, chronic and neuropathic pain.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: October 24, 2006
    Assignee: Akzo Nobel N.V.
    Inventors: John Richard Morphy, Zoran Rankovoc
  • 2-(aminomethyl) arylamide analgesics
    Patent number: 7084154
    Abstract: A chemical genus of 2-(aminomethyl)arylamides, which are useful as analgesics, is disclosed.
    Type: Grant
    Filed: February 11, 2003
    Date of Patent: August 1, 2006
    Assignee: Pharmacopeia Drug Disclovery, Inc.
    Inventors: Koc-Kan Ho, John J. Baldwin, Adolph C. Bohnstedt, Steven G. Kultgen, Edward McDonald, Tao Guo, John Richard Morphy, Zoran Rankovic, Robert Horlick, Kenneth C. Appell
  • N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives
    Publication number: 20040242685
    Abstract: The present invention relates to N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives having the general formula I 1
    Type: Application
    Filed: July 19, 2004
    Publication date: December 2, 2004
    Inventors: John Richard Morphy, Zoran Rankovoc
  • 2-(aminomethyl) arylamide analgesics
    Publication number: 20040167119
    Abstract: A chemical genus of 2-(aminomethyl)arylamides, which are useful as analgesics, is disclosed.
    Type: Application
    Filed: February 11, 2003
    Publication date: August 26, 2004
    Applicant: PHARMACOPEIA, INC
    Inventors: Koc-Kan Ho, John J. Baldwin, Adolph C. Bohnstedt, Steven G. Kultgen, Edward McDonald, Tao Guo, John Richard Morphy, Zoran Rankovic, Robert Horlick, Kenneth C. Appell